After ABO system antigens, RhD is the most clinically significant blood group antigen. This is reflected in its high immunogenicity and potential to cause haemolytic transfusion reactions (HTR) and severe haemolytic disease of the newborn (HDN). Thus, correct determination of the RhD antigen is essential for a safe transfusion strategy and adequate indications of anti-D immunoglobulin prophylactic administration. The RhD determination challenge started in 1939 with a case history of fatal HDN and HTR in a mother who was transfused with her husband 0 s blood. Subsequent findings of an antibody reacting with 80% ABO compatible red blood cells (RBCs) in the serum of the afflicted woman lead to the hypothesis that the mother was lacking an antigen present on the father's and fetal RBCs and that her production of a corresponding antibody was responsible for both HDN and HTR. This hypothesis was proven to be correct. The following year, the effort to determine the origin of a causal antigen coincided with an animal immunization experiment where a similarly reacting antibody developed by injecting Rhesus monkey RBCs into rabbits and guinea-pigs, as well as with another publication of HTRs after ABO compatible blood transfusions in patients with antibodies of apparently identical specificity. This first challenge in the 'pre-DNA' era was slightly erroneously named in humans as the anti-Rhesus antibody, and 20 years later, the animal antibody was designated anti-LW. Meanwhile, the complexity of Rh group of antigens increased and several genetic models were suggested to explain it: Rh-Hr single gene, three genes C, D and E and finally a two locus model (which a few years later was shown by molecular analysis to be the accurate one). At the beginning, serological determination of RhD was performed using human anti-D, first by direct agglutination (IgM), later also using the Coombs' test (IgG). Weak D antigens were a challenge at the time: the term 'D U' (now obsolete) was used for those antigens negative in direct agglutination and positive in the Coombs' test. Weakening of the D antigen could be caused indirectly by the 'position effect C in Trans' or directly (mutations in the RHD gene, usually point mutations coding for amino acids in transmembranous and intracellular parts of the polypeptide). production of numerous different monoclonal anti-Ds. According to patterns of reactivity of different partial Ds after two international workshops, the number of D epitopes reached 30. DNA techniques subsequently helped refine discrimination between partial D types. The number of described D antigen variants will surely rise after this ISBT congress and Working Party meeting. A further increase can be anticipated once NGS will provide new information and more data will come from large Asian and African populations and the polymorphic complexity of RhD and the whole Rh system will expand.
Introduction
RhD belongs together with the ABO system antigens to the most clinically important structures of the red cell membrane. The history of RhD determination is unique in the sense of challenging consecutive diagnostic riddles. Today, almost all Rh enigmas have been uncoveredmainly with the aid of monoclonal antibodies and the introduction of DNA techniques. Still, some challenges remain -new mutations are continuously being described; amino acid substitution effect on the RhD protein structure could be analysed in the future using sophisticated computer crystallographic modelling. The geographically different distribution of RhD-positive and -negative phenotypes has been explained in part as different consequences of heterozygote advantage but the final clarification is still missing.
Historical challenges
The first challenge was to link neonatal icterus cases and haemolytic transfusion reactions with a so far unknown red cell structure. In 1939, a case history [1] of fatal HDN followed by serious HTR in the mother after receiving a blood transfusion from her husband suggested a common inherited immunohaematological cause. The finding of an antibody in the mother's serum reacting with the husband 0 s RBCs and another 80% ABO compatible RBCs supported the existence of a new factor present in the blood of the husband and the affected child, which was lacking in the blood of the mother. An animal immunization experiment reported in 1940 [2] brought the next challenge. An antibody produced in rabbits and guinea-pigs immunized by injecting of Rhesus monkey RBCs seemed to have the same specificity as the antibody from the HDN and HTR case mentioned previously. As the result of this similarity, the human RBC structure was named Rhesus factor, and later, the blood group system was named the Rh system. The difference between these two human and animal antibodies was found several years later, but the original name remained for the human antigen and the one of corresponding to the antibody of animal origin was designated LW.
Challenges with DNA rescue
The following challenge was to solve the inheritance of RhD. This antigen was subsequently coupled with other genetically related antigens and the complexity of the system required explanation using genetic nomenclature. Several genetic models were proposed as follows: Wiener's theory [3] The major cause of the RhD-negative phenotype in the Caucasian population is the RHD gene deletion [9] . Another frequent cause of RhD negativity found in the African population RHD pseudogene was described in 2000 [10] . To date, numerous other rare causes of RhDnegative phenotype were identified/different genetic mechanisms/, and more than 80 are recorded in the RhesusBase [11] . Soon after completing basal genetic information, DNA techniques were introduced into routine practice for RhD genotyping [12, 13] in cases where phenotyping was inconclusive /multitransfused patients, AIHA cases/.
In the early decades of RhD serology determination another challenge appeared -some probands presented a phenotype positive with some but not all anti-D reagents or negative in the direct agglutination phase /IgM anti-D/ and positive in the indirect antiglobulin test with IgG anti-D. This phenotype was originally named D u /now obsolete/ [14] . Some of these weakened phenotypes are caused indirectly by the position of the C antigen coding allele in 'trans' [15] . In cases with direct inheritance, individual alleles with point mutations in the RHD gene causing an amino acid substitution involved in the 'nonexofacial' parts of the RhD protein were identified [16] . These changes result in a significant decrease in the number of RhD protein copies in the RBC membrane. A challenge especially for blood donor typing is the existence of a further RhD phenotype variant -an extreme weakening resulting in impossible detection using routine serology methods, the only option being the use of adsorption-elution. This phenotype was first reported in 1984 [23] and is termed Del or DEL and there are almost 50 alleles to date in the RhesusBase [11] . Based on observations of a pregnancy-related anti-D in some DEL types [24] /, this group includes some 'partial DEL' /cases reported in China were RHD-CE-D hybrid alleles [25] , we have recently observed strong allo-anti-D in a pregnant Caucasian woman with RHD*DEL4 allele/ and 'weak DEL'. A rare case of D-negative recipient who developed anti-D after transfusion of a DEL unit /not recognized by routine serology and thus labelled as D negative [26] / lead to the introduction of routine RHD genotyping in all serologically D-negative blood donors in Switzerland.
Haemolytic disease of the new-born, a complication of pregnancy, is most often linked to RhD negativity of the mother and RhD positivity of the foetus and therefore a precise diagnostic for mothers, foetuses/newborns and in some cases fathers presents another challenge. The introduction of postnatal anti-D prophylactic administration of anti-D in 1970s dramatically reduced HDN incidence and further reduction could be achieved using antenatal prophylaxis. Knowledge of the RhD status of the foetus is important for justified prophylaxis administration. DNA techniques now allow either to predict foetus status indirectly by determining the father's homo-/hemi-/heterozygosity or directly by fetal genotyping from fetal DNA isolated from the maternal plasma [27] .
At present, most of the weak/partial D cases could be resolved using the combined efforts of serology /kits of monoclonal anti-D's/ and genotyping /routine RHD genotyping kits and arrays/. Rare cases of discrepant or inconclusive results present the next challenge. In such cases, sequencing is necessary /established methods of pyrosequencing, Sanger sequencing and upcoming Next-Generation Sequencing/. Possible results in discrepant cases are either known rare mutations /not detectable with the combination of primers used in genotyping kits/ or as yet undiscovered new ones. At the Toronto ISBT congress, we presented two new mutations /RHD(L228P) and RHD (E369K)/ and during the investigation of these cases, we faced another challenge. When we placed the amino acid substitution into an older two-dimensional model of the D protein, they appeared to be located intramembraneously, predicting weak D type / The remaining challenge after 70 years of RhD history is to elucidate why the evolutionary younger and immunohaematologically disadvantageous /because of HDN/ RhD-negative phenotype has attained a relatively high frequency in the European population compared to African and Asian populations. An interesting theory supported by statistically significant data links the propagation of RhD-negative phenotype to infection by the parasite Toxoplasma gondii [28] . RhD-negative individuals, Toxoplasma-free showed better reaction times and these dramatically worsened after infection. In Toxoplasma-infected RhD-positive hemizygotes, this worsening was significantly milder. This could be related with the propagation of RhD positivity during mammalian evolution /after duplication of the ancestral RH gene/. During hominid evolution, the new 'deleted' RhD-negative phenotype had an advantage of lower reaction time / good for hunting, fighting, escaping/ and a much better chance to propagate in Europe where the chance to acquire Toxoplasma from the host /feline excrements/ was much lower than in Africa and Asia. Statistical significance is interesting but one piece of the chain is missing -how to link the erythroid-only expression of RhD with this neuromuscular effect.
Conclusion
RhD determination is still an active field with many challenges remaining -developing new reagents, kits and arrays for serology and DNA analysis. Immunohaematological automatic analysers using microchip technology and Next-Generation Sequencing could bring many new discoveries in the near future. Even more advanced computing of models of proteins embedded in the lipid membrane may help to create hypothetical amino acid substitutions and predict possible as yet unidentified RhD variants. New findings could bring better care for transfusion recipients, pregnant women and their foetuses/newborns and because of frequent anti-Rh specificity of warm autoantibodies also for patients with WAIHA.
